Please login to the form below

Not currently logged in
Email:
Password:

Algeta execs join Targovax

Anna-Kirsti Aksnes and Tina Madsen join the firm

Norway's Targovax has added to its senior team with the appointment of two executives from Algeta.

Anna-Kirsti Aksnes joins the cancer immunotherapy specialist as VP clinical development and Tina Madsen joins as VP quality assurance.

Aksnes was most recently VP clinical research at Algeta, which was taken over by pharma giant Bayer in 2014. In her role she helped lead strategic, scientific, clinical development and medical communications for the company.

Madsen joins as VP quality assurance, joining from the position of director of product quality assurance. She has over 20 years of experience in the life sciences industry.

Commenting on the appointments, Targovax's CEO Gunnar Gardemyr said: “I am pleased to welcome Anne-Kirst and Tina to our team. We look forward to the insight and wealth of experience that they bring to Targovax.”

29th January 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics